Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.49 |
| ▸ | IDO1 | P14902 | 4/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18714303 | 0.80 | METAP2 (0.58) | METAP2IDO1TRPA1TDO2CYP1A2 | |
| SCHEMBL459141 | 0.79 | IDO1 (0.56) | METAP2IDO1NOS1DYRK1ATRPA1 | |
| SCHEMBL20176610 | 0.79 | METAP2 (0.42) | METAP2IDO1TRPA1TDO2CYP1A2 | |
| SCHEMBL30856325 | 0.79 | METAP2 (0.49) | METAP2IDO1TRPA1TDO2CYP1A2 | |
| SCHEMBL15808384 | 0.79 | METAP2 (0.49) | METAP2IDO1TRPA1TDO2CYP1A2 | |
| SCHEMBL14487466 | 0.75 | METAP2 (0.56) | METAP2IDO1NOS1DYRK1ATDO2 | |
| SCHEMBL21267264 | 0.75 | METAP2 (0.52) | METAP2IDO1TRPA1TDO2CYP1A2 | |
| SCHEMBL17739410 | 0.72 | METAP2 (0.53) | METAP2IDO1NOS1DYRK1ATDO2 | |
| SCHEMBL16682088 | 0.72 | METAP2 (0.53) | METAP2IDO1NOS1DYRK1ATDO2 | |
| SCHEMBL2003535 | 0.72 | METAP2 (0.53) | METAP2IDO1NOS1DYRK1ATDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | METAP2 4127/4885IDO1 4606/4885NOS1 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.